BioSpace News Archive

XVIVO Perfusion AB, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO’s clinical trial, NIHP2019, in heart transplantation were presented.

Zymeworks Inc. announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.

RaySearch Laboratories AB announces that QST, National Institutes for Quantum Science and Technology in Chiba, Japan, has selected the treatment planning system RayStation®* for clinical use at the QST hospital.

Tiziana Life Sciences Ltd. announced an upcoming oral presentation, titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” that will be presented during the “Multiple Sclerosis: Therapeutics and Clinical Decision Making” session at the Annual Meeting of the American Academy of Neurology, to be held April 13-18, 2024 in Denver, Colorado.

Fortrea, a leading global contract research organization, announced that it will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

Algernon Pharmaceuticals Inc., is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April 16th, 2024, at 4 PM ET / 1 PM PT, hosted by Market Radius Research.

Century Therapeutics announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.

Labcorp, a global leader of innovative and comprehensive laboratory services, announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.

ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners is pleased to announce that it has welcomed Kirk Wroblewski as its new Chief Information Officer and Andrew Shaw as General Counsel.

Lipocine Inc., a biopharmaceutical company, announced results from a Phase 2 clinical trial which includes LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant.